Oculis Announces Public Listing After Completing Business Combination Between European Biotech Acquisition Corp. And Oculis SA
CFGI’s Capital Markets team assisted Oculis Holding AG (“Oculis”) with its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp.
Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market
CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.
CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.
CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.